Why does a peptide protocol need bloodwork?
First, a quick definition, because the word gets thrown around loosely. A peptide is just a small chain of amino acids — the same building blocks that make up proteins — that acts as a signal in the body. Some peptides nudge the system that controls growth and repair. The popular weight and blood-sugar medicines you have heard of, like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are in the same family: they are sometimes grouped under "GLP-1" therapies, and they work by copying a natural gut signal. A "protocol" is simply the plan a clinician sets — which compound, what dose, and how often.
Here is why blood tests come along for the ride. These compounds do not act in one tidy spot and leave everything else alone. They touch systems that show up in your blood: how your body handles sugar, your cholesterol, how hard your liver and kidneys are working, and in some cases your hormones. Bloodwork is how a clinician watches those systems respond — to confirm the plan is helping, and to catch anything drifting the wrong way early, while it is still easy to address.
There is also a baseline reason. A test done before you start gives your clinician a "before" picture. Without that starting point, a single number later on is hard to judge — you cannot tell whether it went up, went down, or never moved. That is the quiet theme of this whole page: a lab value means very little as a lone snapshot. It means something as part of a panel, compared against your own earlier results, and read by someone who can see the rest of your picture.
What markers does a clinician actually watch?
There is no single "peptide panel" that every clinic orders. The exact list depends on the compound, your health history, and why you are on the protocol. But a typical panel pulls from a few groups, and it helps to see them laid out before we go through each one.
The glycemic and metabolic group covers how your body manages energy: fasting glucose (your blood sugar after not eating), HbA1c (your average blood sugar over the past few months), and a cholesterol or lipid panel. The organ-function group checks the two organs that do the heavy lifting of processing things: the liver (through enzymes called ALT and AST) and the kidneys (through a number called eGFR). And where it is relevant, a hormone group is added — IGF-1 for peptides that act on the growth-hormone system, or testosterone along with a protein called SHBG when male hormone levels are part of the picture.
One note before the numbers, and it is the single most important caveat on this page. The example ranges below are reference ranges, and reference ranges are not universal. They depend on the laboratory, the machine, and the method used to run the test. Different labs genuinely print different "normal" ranges for the same marker. So treat every figure here as a common reference point for orientation, not a hard line — your own lab report prints its own ranges, and a clinician reads your result against those.
| Marker | What it reflects | General reference point (lab-dependent) |
|---|---|---|
| Fasting glucose | Blood sugar after not eating — a snapshot | Normal <100 mg/dL; 100–125 prediabetes; ≥126 diabetes (ADA) |
| HbA1c | Average blood sugar over ~2–3 months | Normal <5.7%; 5.7–6.4% prediabetes; ≥6.5% diabetes (ADA) |
| ALT / AST | Liver-cell stress — enzymes leak into the blood | Upper limit varies by lab (~35–79 U/L for men) |
| eGFR | How well the kidneys filter blood | ≥90 generally normal; <60 for 3+ months suggests CKD (NKF) |
| IGF-1 | A steadier stand-in for growth-hormone activity | Age-, sex- and assay-dependent — no universal number |
| Total testosterone (with SHBG) | Male hormone level; SHBG sets how much is free to act | ~264–916 ng/dL in healthy men 19–39, assay-calibration dependent |
What do the glycemic and metabolic markers mean?
Start with blood sugar, because it is the most commonly watched group on these protocols. Fasting glucose is your blood sugar level after roughly 8 to 12 hours with no food and only water. Think of it as a single snapshot. HbA1c — say it "H-B-A-one-C," also written A1C — is the longer view: sugar in your blood sticks to a protein inside your red blood cells, and because those cells live a few months, the amount stuck to them reflects your average blood sugar over roughly the past two to three months. A snapshot versus a time-lapse.
The American Diabetes Association, a leading clinical group, publishes widely used reference points for both. For fasting glucose: below 100 milligrams per deciliter (mg/dL) is considered normal, 100 to 125 mg/dL falls in the prediabetes range, and 126 mg/dL or higher (confirmed on more than one occasion) meets the line for diabetes. For HbA1c: below 5.7 percent is normal, 5.7 to 6.4 percent is the prediabetes range, and 6.5 percent or higher meets the diabetes line. On a GLP-1 protocol a clinician often wants to see these trending in a healthy direction over time — but, again, the trend across visits tells the story, not one isolated reading.
The metabolic group usually also includes a lipid panel — your cholesterol numbers. Two worth naming in plain words: triglycerides, which are a type of fat that circulates in your blood, and HDL, often called the "good" cholesterol. We are deliberately not putting cutoff numbers on these here, because the exact thresholds vary by guideline and by your personal risk, and that judgment belongs to your clinician. The useful idea is simpler: a clinician watches whether the overall lipid picture is moving in a healthy direction on the protocol, not whether one number crossed a line on one day.
What about the liver and kidney markers?
These two organ-function groups are on the panel because the liver and kidneys do the body's processing and filtering, so they are worth keeping an eye on whenever someone starts a long-running therapy.
Liver enzymes are usually reported as ALT and AST. ALT stands for alanine aminotransferase and AST for aspartate aminotransferase — both are enzymes, which are proteins that speed up chemical reactions, and both live mostly inside liver cells. When liver cells are stressed or damaged, some of these enzymes leak into the blood, so a higher level can be a flag worth looking into. But here the "normal range" caveat is especially sharp. Research has shown that the upper limit of normal for ALT genuinely differs from lab to lab depending on the local population each lab used to set its range — one study found the upper limit reported across labs ranged from roughly 35 to 79 units per liter for men, meaning the very same blood sample could be read as anywhere from well within normal to clearly high depending only on which lab ran it. That is a vivid example of why you cannot judge a liver enzyme against a number you found online.
Kidney function is usually summarized by eGFR, which stands for estimated glomerular filtration rate. In plain words it is an estimate of how well your kidneys are filtering your blood, calculated from a blood test (creatinine) along with your age and other factors. According to the National Kidney Foundation, an eGFR of 90 or higher is generally considered normal kidney function. A reduced eGFR — particularly below 60 sustained for three months or more, or any reduction alongside other signs of kidney damage — is what defines chronic kidney disease and prompts a closer look. As with every marker here, one eGFR reading is a data point, not a diagnosis; clinicians look at the trend and the rest of the picture.
What about hormone markers?
Hormone markers only belong on the panel when they are relevant to the specific protocol — they are not part of every peptide-therapy workup. A hormone, to define the term, is just a chemical messenger that travels in your blood and tells parts of your body what to do.
For peptides that act on the growth-hormone system — the family that includes compounds meant to nudge the body's own growth-hormone and repair signaling — the marker a clinician usually tracks is IGF-1, short for insulin-like growth factor 1. IGF-1 is a steadier stand-in for growth-hormone activity, because growth hormone itself comes out in quick bursts that are hard to capture in one blood draw. We are intentionally not printing IGF-1 "normal" numbers on this page, and the reason is itself a lesson: IGF-1 reference ranges depend heavily on your age and sex, and they differ markedly between testing machines. In one study that ran the same blood through six different commercial IGF-1 tests, the upper end of the normal range varied a lot from machine to machine. So an IGF-1 result only means something next to the range from the exact lab that ran it.
When male hormones are part of the picture, the clinician usually looks at total testosterone together with a protein called SHBG — sex hormone-binding globulin, which is the protein that carries testosterone around in your blood and controls how much of it is actually free to act. For total testosterone, a large harmonized study of healthy young men (ages 19 to 39) put the normal range at roughly 264 to 916 nanograms per deciliter (ng/dL), but with an important condition: that figure applies to tests calibrated to a shared national standard, and labs that are not calibrated that way can read quite differently. This is exactly where one number misleads most often. The Endocrine Society, a leading hormone-specialist group, recommends not diagnosing low testosterone from a single draw at all — it calls for symptoms plus consistently low levels measured on two separate mornings while fasting, because testosterone naturally varies through the day. And because SHBG can shift with age, weight, and other conditions, the Society advises measuring free or "bioavailable" testosterone (the portion actually available to your tissues) when SHBG might be skewing the total. In plain terms: the total number alone can look reassuring or alarming and still be the wrong thing to judge.
Why a "normal" number can still mislead
This is the idea worth reading twice, because it is the honest heart of the whole topic. A result printed inside the "normal range" can still miss what is actually going on — and so can a single result printed outside it.
There are a few reasons. First, "normal range" is not a personal target; it is a band that covers most people in some reference group. A value can be technically in range for the population and still be off for you, especially if it has moved a long way from your own earlier baseline. A testosterone that landed just inside the bottom of the range, in a man with clear symptoms, can mean something a population chart cannot see. Second, ranges vary by lab, sometimes a lot — you saw it with liver enzymes, where the same sample could read as normal or high depending only on which lab ran it, and with IGF-1 and testosterone, where the assay and calibration change the number. Comparing your result to a number from a different lab, or from the internet, can quietly mislead you.
Third, and most important: one marker rarely tells the story by itself. A normal fasting glucose with a creeping HbA1c says something different than either number alone. A single eGFR dip after a dehydrated morning is not the same as a steady downward trend. The meaning lives in the pattern — several markers together, tracked over time, alongside things a lab value cannot see, like your symptoms, your weight trend, your other results, and what you did the day before the draw. Pulling those threads together into a judgment is exactly what a licensed clinician is trained for, and it is why none of this is something to settle from a printout on your own.
How to track it over time
If there is one practical habit that makes a peptide-therapy panel useful, it is this: keep the history. A single result is a snapshot, and snapshots are easy to misread. The real signal is the trend — how each marker moves across your baseline, your three-month check, your six-month check, and beyond. A clinician who can see that line can tell the difference between a one-off blip and a genuine direction, which is something no single test can show.
That also means a little consistency pays off. Where possible, having the same marker run by the same lab on the same kind of test makes the trend trustworthy, because a change in the number then reflects a change in you rather than a change of machine — this matters most for the markers we flagged as assay-dependent, like IGF-1 and testosterone. And the work of interpreting any of it stays with your clinician, who reads the trend against your symptoms and your whole picture. Everything on this page is education, not medical advice, and not a substitute for that conversation.
Keeping the panel organized with PeptidePanel
The hard part of all this is rarely any single test — it is keeping the history straight. Lab results pile up across PDFs, portals, and appointments, and the trend that actually matters gets lost in the shuffle. One number out of context is exactly the thing this whole page warns against.
PeptidePanel is a simple tracking tool for that job. You enter your results — glucose, HbA1c, liver and kidney markers, IGF-1, testosterone, and the rest — and it charts each one over time next to its reference range, so a slow drift across months is as easy to see as a single out-of-range value. It does not diagnose, prescribe, or sell any medicine or supplement, and it is not a substitute for your clinician. It is simply the organized notebook that keeps your protocol's bloodwork in one place and makes your next appointment more useful.